Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Commercial Sponsor
MedImmune, LLC
Summary
This study aims to assess the safety, tolerability and dosing of MEDI2888 for treatment of multiple myeloma in adults who are transplant ineligible or have recurrent Multiple Myeloma. Patients eligible to participate in this study will receive a specific dose of MEDI2228.